SARS-CoV-2 virus-like particle as well as preparation method and application thereof

The expression of S, M and E proteins in Sf9 cells through baculovirus expression system and Bac to Bac technology to form SARS-CoV-2 virus-like particles VLPs, which solves the preparation of SARS-CoV-2 virus-like particles in the prior art. Safety, efficiency and economic issues have achieved effective COVID-19 vaccine development and immune response.

CN119061028AActive Publication Date: 2024-12-03YANGZHOU UNIV

Patent Information

Application Number
CN202410994117.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-12-03
Estimated Expiration
2044-07-24

AI Technical Summary

Technical Problem

The prior art is difficult to prepare SARS-CoV-2 virus-like particles safely, efficiently and economically, resulting in the lack of effective COVID-19 vaccine solutions.

Method used

Using Bac to Bac technology in the baculovirus expression system, recombinant plasmids are constructed and transformed, S, M and E structural proteins are expressed, and Sf9 insect cells are used for co-infection to form SARS-CoV-2 virus-like particles VLPs, and Purification and immunoelectromicroscopy by sucrose density gradient ultracentrifugation and identification of immunoelectromicroscopy, combined with ACE2 binding activity detection, ensure that its structural and biological characteristics are similar to that of natural products.

Benefits of technology

It has achieved safe and efficient preparation of SARS-CoV-2 virus-like particles, has good immunogenicity, is suitable for mucosal immunization, reduces vaccination and production costs, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061028A_ABST
    Figure CN119061028A_ABST
Patent Text Reader

Abstract

The invention discloses an SARS-CoV-2 virus-like particle as well as a preparation method and application thereof. The gene for coding the structural protein of the novel coronavirus comprises an S gene, an M gene or an E gene; the nucleotide sequence of the S gene is as shown in SEQ ID NO. 1; the nucleotide sequence of the M gene is as shown in SEQ ID NO. 2; and the nucleotide sequence of the E gene is as shown in SEQ ID NO. 3. The invention provides a virus-like particle (VLP) for the first time, and the VLP is formed by self-assembly after three structural proteins of SARS-CoV-2 virus S, M and E are expressed by a baculovirus-insect cell expression system; the invention solves the problem that a safe and effective VLP vaccine for preventing and controlling COVID-19 does not exist at present; the VLP is suitable for mucous membrane way immunization, the immunization effect is improved, the vaccination and labor cost can be reduced, and the VLP has potential economic benefits.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a SARS-CoV-2 virus-like particle and a preparation method and application thereof, belonging to the field of biotechnology. Background Art

[0002] The new coronavirus (SARS-CoV-2) is a single-stranded RNA virus belonging to the beta coronavirus family. It can encode 29 proteins, including 4 structural proteins and 25 non-structural and auxiliary proteins. The four main structural proteins of SARS-CoV-2 are spike protein (S), nucleocapsid protein (N), membrane protein (M), and envelope protein (E). The S protein is composed of two functional subunits, S1 and S2. The receptor binding domain (RBD) in the S1 subunit binds to angiotensin-converting enzyme 2 (ACE2) on the host cell membrane to mediate the virus' entry into host cells (Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells [J]. Nat Rev Mol Cell Biol, 2022, 23 (1): 3-20.). Therefore, the S protein is the main target for the development of a new coronavirus vaccine.

[0003] As of March 2023, 183 COVID-19 vaccines have entered the clinical stage. Among them, subunit vaccines account for the largest number, accounting for 32%. Virus-like particles (VLPs) are highly structured protein particles assembled by single or multiple structural proteins of the virus. They do not contain viral genetic material and have no risk of reverse mutation or pathogenic infection. VLPs can stimulate the immune system by recognizing repeating subunits, producing cellular and humoral immune responses ( A, Mellado MC, Castilho LR, et al. Virus-like particles in vaccine development [J]. Expert Rev Vaccines, 2010, 9 (10): 1149-1176.). Currently, several vaccines based on VLPs have been commercialized, such as recombinant hepatitis B virus vaccine, human papillomavirus vaccine and porcine circovirus type 2 vaccine, but there is still no report on the market launch of SARS-CoV-2 VLP vaccine.

[0004] Systems commonly used to express VLPs include bacteria, yeast, insect cells, and mammalian cells. Bacteria and yeast are favored for their rapid growth and high yield, but they cannot provide complex post-translational modifications. Mammalian cells have high production costs and low production efficiency (Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines [J]. N Biotechnol, 2017, 39 (Pt B): 174-180.). For decades, the baculovirus expression system has been effectively used in vaccine production and gene therapy as a mature exogenous protein expression platform. Its advantages are that the system can be mass-produced at low cost, and BEVS can insert large exogenous DNA fragments, express multiple exogenous proteins at the same time, and provide appropriate post-translational modifications (Hong Q, Liu J, Wei Y, et al. Application of baculovirus expression vector system (BEVS) in vaccine development [J]. Vaccines (Basel), 2023, 11 (7): 1218.).

[0005] In summary, it is urgent to develop a method that can safely, efficiently and economically prepare SARS-CoV-2 virus-like particles to provide technical and product support for the global prevention and control of infections with the new coronavirus and its variants. Summary of the invention

[0006] Purpose of the invention: The technical problem to be solved by the present invention is to provide for the first time a SARS-CoV-2 virus-like particle and a preparation method and application thereof.

[0007] Technical solution: To solve the above technical problems, the present invention provides a gene encoding a structural protein of a new coronavirus, wherein the gene of the structural protein includes an S gene, an M gene or an E gene; the nucleotide sequence of the S gene is shown in SEQ ID NO.1; the nucleotide sequence of the M gene is shown in SEQ ID NO.2; the nucleotide sequence of the E gene is shown in SEQ ID NO.3.

[0008] The invention also provides a structural protein encoded by the gene.

[0009] The invention also provides an expression box, a recombinant vector and a recombinant virus containing the gene of the structural protein.

[0010] The present invention also provides a recombinant bacmid, which contains the recombinant vector.

[0011] The present invention also provides a recombinant baculovirus, which contains the recombinant bacmid.

[0012] The present invention also provides a novel coronavirus virus-like particle, which is prepared by purifying Sf9 cells infected with the recombinant baculovirus.

[0013] The present invention also provides a method for constructing the novel coronavirus virus-like particles, comprising the following steps: respectively transforming the recombinant vectors containing the S gene, the M gene or the E gene into competent cells, respectively transfecting the recombinant bacmids into Sf9 cells, and co-infecting the Sf9 cells with the recombinant baculovirus to obtain the novel coronavirus virus-like particles.

[0014] The present invention further provides a method for preparing VLPs, which comprises the following steps:

[0015] 1. Prepare baculovirus P2-S and P2-ME using Bac to Bac technology in baculovirus expression system. The specific steps are as follows:

[0016] 1. Construction and identification of recombinant plasmids:

[0017] (1) SARS-CoV-2 S, M, and E gene codon optimization;

[0018] (2) Synthesize the S gene into the pFastBac1 vector to obtain the recombinant plasmid pFastBac1-S;

[0019] (3) The M and E genes were synthesized into the pFast-Dual vector to obtain the recombinant plasmid pFast-Dual-ME;

[0020] (4) PCR identification of recombinant plasmid.

[0021] 2. Transformation of recombinant plasmids: The recombinant plasmids pFastBac1-S and pFast-Dual-ME were transformed into DH10Bac competent cells to obtain positive recombinant bacmids Bacmid-S and Bacmid-ME.

[0022] 3. Preparation of recombinant baculovirus:

[0023] (1) Recombinant bacmid extraction and PCR identification;

[0024] (2) Recombinant bacmids Bacmid-S and Bacmid-ME were transfected into Sf9 insect cells, and the obtained supernatant was the P1 generation baculovirus;

[0025] (3) The P1 generation baculovirus was used to infect Sf9 cells again at a low MOI, and the supernatant obtained was the P2 generation baculovirus, named P2-S and P2-ME;

[0026] (4) Use BacPAK Baculovirus Rapid Titer Kit to detect the titer of recombinant baculovirus.

[0027] 4. Identification of S, M and E protein expression:

[0028] (1) Indirect immunofluorescence identification;

[0029] (2) Western Blotting identification.

[0030] 2. Preparation, purification and identification of SARS-CoV-2 virus-like particle (VLP) vaccine

[0031] 1. Co-transfect Sf9 cells with P2-S and P2-ME.

[0032] 2. Purify VLPs using sucrose density gradient ultracentrifugation.

[0033] 3. SARS-CoV-2 VLPs identification:

[0034] (1) Western Blotting identification;

[0035] (2) Transmission electron microscopy observation;

[0036] (3) Immunoelectron microscopy observation;

[0037] (4) ACE2 binding activity.

[0038] 3. Study on the immunogenicity of SARS-CoV-2 VLPs

[0039] 1. Animal immunization and sample collection;

[0040] 2. Detection of IgG and IgG subtypes in mouse serum;

[0041] 3. Mouse serum neutralizing antibody detection;

[0042] 4. Proliferation capacity of mouse spleen lymphocytes;

[0043] 5. Splenic lymphocyte ELISpot was used to detect the number of lymphocytes secreting IFN-γ and IL-4 cytokines.

[0044] The present invention also provides the use of the S gene, the M gene or the E gene, the structural protein, the expression cassette, the recombinant vector or the recombinant virus, the recombinant bacmid, the recombinant baculovirus, and the novel coronavirus virus-like particle in the preparation of a vaccine for preventing novel coronavirus infection.

[0045] The present invention also provides the use of the S gene, the M gene or the E gene, the structural protein, the expression cassette, the recombinant vector or the recombinant virus, the recombinant bacmid, the recombinant baculovirus, and the novel coronavirus virus-like particle in the preparation of a drug for treating and / or preventing novel coronavirus infection.

[0046] In summary, the SARS-CoV-2 VLPs formed by self-assembly after the expression of S, M, and E proteins by co-infection of P2-S and P2-ME recombinant viruses in Sf9 insect cells in the present invention have similar structures and biological properties to natural products and good immunogenicity. After being mixed with flagellin (FliC) adjuvant to prepare vaccines for immunizing mice, the immune response level of VLPs was further enhanced, and strong humoral and cellular immune responses were induced. The vaccines have high safety, are of great significance to the development of COVID-19 vaccines, and have broad application prospects.

[0047] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: 1. The present invention provides a virus-like particle (VLP) for the first time, which is self-assembled after the three structural proteins S, M and E of the SARS-CoV-2 virus are expressed by a baculovirus-insect cell expression system; 2. The present invention solves the problem that there is currently no safe and effective VLP vaccine for the prevention and control of COVID-19; 3. The VLP in the present invention is suitable for mucosal immunization, which can improve the immune effect and reduce vaccination and labor costs, and has potential economic benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 PCR identification diagram of recombinant plasmids pFastBac1-S and pFastBac-Dual-ME, where (A) is pFastBac1-S, (B) pFastBac-Dual-ME, (C) pFastBac-Dual-ME, M is DL5000 DNA marker, 1 is S gene amplification product, 2 is M gene amplification product, 3 is E gene amplification product;

[0049] Figure 2 PCR identification of recombinant bacmids Bacmid-S and Bacmid-ME, where (A): Bacmid-S, (B) Bacmid-ME, (C): Bacmid-ME, M: DL5000 DNA marker, 1: SF / pUC / M13-R as primers, 2: SF / R as primers, 3: MR / pUC / M13-R as primers, 4: MF / R as primers, 5: EF / pUC / M13-R as primers, 6: EF / R as primers;

[0050] Figure 3 The titer determination results of recombinant baculovirus P2-S and P2-ME, where (A) is the titer result of P2-S virus, (B) is the titer result of P2-ME virus, a is the negative control, b is the virus diluted to 10 -3 The infection focus at the time of infection, c: virus diluted to 10 -4 Infection focus at time d: virus diluted to 10 -5 The infection focus at that time;

[0051] Figure 4 The results of indirect immunofluorescence experiments of S, M and E protein expressions, where (A) identifies the expression of S protein, (B) identifies the expression of M protein, and (C) identifies the expression of E protein.

[0052] Figure 5 The Western Blotting results of S, M and E protein expression, where M: protein marker, 1, 3, 5: negative control, 2: identification of S protein expression, 4: identification of M protein expression, 6: identification of E protein expression;

[0053] Figure 6 Purification of SARS-CoV-2 VLPs and Western Blotting identification, where (A): VLPs after sucrose density gradient ultracentrifugation, (B): Western Blotting identification of purified VLPs, M: protein marker, 1: samples between 20%-30% sucrose density, 2: samples between 30%-60% sucrose density;

[0054] Figure 7 Transmission electron microscopy images of SARS-CoV-2 VLPs in different fields of view;

[0055] Figure 8 Immuno-electron microscopic images of SARS-CoV-2 VLPs in different fields of view;

[0056] Fig. 9 This is a graph showing the ACE2 binding activity of VLPs;

[0057] Fig.10 This is the IgG antibody detection chart in mouse serum 12 days after the second and third immunizations;

[0058] Fig.11 This is the detection diagram of IgG antibody subtypes in mouse serum 12 days after triple immunization;

[0059] Fig.12 It is the level of neutralizing antibodies against RBD protein in the mouse serum 2 weeks after the three immunizations;

[0060] Fig.13 The results of the mouse spleen lymphocyte proliferation experiment were shown two weeks after the triple immunization.

[0061] Fig.14 The results are shown in Figure 1. These are the ELISpot results of spleen lymphocytes 2 weeks after the triple immunization. DETAILED DESCRIPTION

[0062] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.

[0063] Example 1 Preparation of baculovirus P2-S and P2-ME using Bac to Bac technology in baculovirus expression system

[0064] 1. Construction and identification of recombinant plasmids

[0065] (1) Gene sequences were optimized according to the insect cell codon preference. The optimized S gene (as shown in SEQ ID NO.1), M gene (as shown in SEQ ID NO.2) and E gene (as shown in SEQ ID NO.3) were synthesized by GenScript Biotech Co., Ltd. into the pUC57 vector. The synthesized vectors: pUC57-S sequence is shown in SEQ ID NO.4, pUC57-M sequence is shown in SEQ ID NO.5, and pUC57-E sequence is shown in SEQ ID NO.6. The optimized S, M and E genes were amplified with SF / R, MF / R and EF / R primers, respectively (primer sequences are shown in Table 1). To facilitate subsequent identification, a 6×His tag was added after the M gene, and a Flag tag was added after the S gene and the E gene. The PCR reaction system was: 2×Taq Master Mix 11μL, ddH2O 11μL, 1μL of upstream and downstream primers, 1μL of plasmid, and a total system of 25μL. The PCR reaction program was: 95°C, 3 min; 95°C, 30 s, 70°C, 30 s; 72°C, 4 min, 34 cycles; 72°C, 10 min. The PCR products were recovered respectively; at the same time, the pFastBac1 plasmid and pFastBac-Dual plasmid were double-digested with restriction endonucleases (the PH promoter was digested with EcoR I and Hind III, and the p10 promoter was digested with Xho I and Kpn I), the digestion system was: 2 μL of each restriction endonuclease, 2.5 μL of 10×M Buffer, 20 μL of plasmid, 50 μL of dd H2O, digestion at 37°C for 3 h, and the digestion products were recovered; ClonExpressUltra One Step Cloning Kit (Vazyme, C116-02) was used to connect the S gene to the pFastBac1 plasmid after digestion, and the M and E genes were connected to the pFastBac-Dual plasmid after digestion (the M gene was connected behind the p10 promoter, and the E gene was connected behind the PH promoter). The one-step ligation system is: 1 μL of target fragment, 9 μL of vector, 10 μL of 2×ClonExpress Ultraone step cloning Mix, and ligation at 50°C for 10 min; the ligation products are transformed into DH5α competent cells, spread on 100 μg / mL ampicillin-resistant LB solid culture medium, and cultured inverted in a 37°C constant temperature incubator overnight.

[0066] Table 1 Primers for amplifying S, M, and E genes

[0067]

[0068] (2) Identification of recombinant plasmids: Pick a single colony, extract pFastBac1-S and pFastBac-Dual-ME plasmids for PCR identification, use SF / R as primers to identify pFastBac1-S; use MF / R as primers to identify the M gene sequence in pFast-Dual-ME, and use EF / R as primers to identify the E gene sequence in pFast-Dual-ME (see Table 1 for primer sequences). The reaction system is: 2×Taq Master Mix 11μL, ddH2O 11μL, 1μL of upstream and downstream primers, 1μL of extracted recombinant plasmid, and a total system of 25μL. The PCR reaction program is: 95℃, 3min; 95℃, 30s, 70℃, 30s; 72℃, 4min, 34 cycles; 72℃, 10min. The results showed that the corresponding target genes were amplified using different primers, and the band sizes were consistent with expectations ( Figure 1 ), indicating that the recombinant plasmids pFastBac1-S and pFast-Dual-ME were successfully constructed.

[0069] 2. Screening of recombinant bacmids

[0070] (1) The recombinant plasmids pFastBac1-S and pFast-Dual-ME were transformed into DH10Bac competent cells to obtain positive recombinant bacmids Bacmid-S and Bacmid-ME. The specific steps are as follows: thaw the DH10Bac competent cells on an ice-water mixture, add 1 μL of the recombinant plasmids pFastBac1-S and pFast-Dual-ME, incubate on ice for 30 min, heat shock at 42°C for 90 s, then stand in the ice-water mixture for 2 min, add 900 μL of LB medium preheated at 37°C, and culture in a shaker at 37°C and 180 r / min for 4 h; dilute the bacterial solution to 10 -2 Afterwards, it was spread on a triple-antibody LB solid culture medium containing 50 μg / mL kanamycin, 7 μg / mL tetracycline, 10 μg / mL gentamicin, 40 μg / mL IPTG and 200 μg / mL X-Gal, and inverted in a 37°C constant temperature incubator for 48 h; a well-shaped and larger white single colony was selected from the above plate, and the white spot was purified by the three-zone streak method until no blue spots appeared.

[0071] (2) Extraction of recombinant bacmids Bacmid-S and Bacmid-ME.

[0072] (3) Identification of recombinant bacmids: SF and pUC / M13-R were used as primers and SF / R was used to identify Bacmid-S; MR and PUC / M13-R were used as primers and MF / R was used as primers to identify the M gene sequence in Bacmid-ME; EF and pUC / M13-R were used as primers and EF / R was used as primers to identify the E gene sequence in Bacmid-ME (Table 1). The reaction system was: 2×Taq Master Mix 11μL, ddH2O 11μL, 1μL of upstream and downstream primers, 1μL of extracted recombinant bacmid, and a total system of 25μL. The PCR reaction conditions were: 95℃, 3min; 95℃, 30s, 70℃, 30s; 72℃, 4min, 34 cycles; 72℃, 10min. The results showed that the target gene of the corresponding size was amplified using different primers, which was consistent with expectations ( Figure 2 ).

[0073] 3. Preparation of recombinant baculovirus

[0074] (1) Insect cell culture: Sf9 cells (stored by the Jiangsu Provincial Key Laboratory of Zoonoses) were inoculated into a 6-well cell culture plate to a cell density of about 70% and cultured in a 27°C incubator for 1 h. The cell culture medium was replaced with 0.8 mL of plate culture medium (Sf-900 containing 1.5% FBS). TM ⅡSFM); prepare transfection reagent: take 4 clean sterile centrifuge tubes, add 100μL Sf-900 without serum and antibiotics to each tube TM Ⅱ SFM medium, used to dilute the recombinant bacmid and transfection reagent. Add 16μg Bacmid-S and Bacmid-ME to two centrifuge tubes respectively, and gently pipette to mix; add 8μL LipoInsect TM Gently pipette and mix the transfection reagent. Let the diluted Bacmid (Bacmid-S and Bacmid-ME) and transfection reagent stand at room temperature for about 5 minutes. Gently add the diluted Bacmid to the diluted LipoInsect TM Add 200 μL LipoInsect to each well. TM The transfection reagent-Bacmid mixture was added dropwise to the wells and mixed; after incubation at 27°C for 4 hours, fresh complete Sf-900 was used. TMⅡ SFM (containing 10% FBS and 1% penicillin-streptomycin), continue to culture at 27°C for about 96 hours, collect the culture fluid from each well, centrifuge at 1000 r / min for 10 min, and the supernatant obtained is the P1 generation baculovirus (P1-S and P1-ME); the P1 generation baculovirus is used to infect Sf9 cells again at MOI = 0.1, collect the culture fluid from each well, centrifuge at 1000 r / min for 10 min, and the supernatant obtained is the P2 generation baculovirus (P2-S and P2-ME).

[0075] (2) Use BacPAK Baculovirus Rapid Titer Kit to detect the recombinant baculovirus titer. The specific steps are detailed in the instructions. The P2-S virus titer was calculated to be 1.92×10 8 IFU / mL, P2-ME virus titer is 1.8×10 8 IFU / mL Figure 3 ).

[0076] 4. Identification of S, M and E protein expression

[0077] (1) Indirect immunofluorescence method: P2-S virus and P2-ME virus were used to infect Sf9 cells in 24-well cell culture plates, respectively. After 96 hours, the cell culture supernatant was collected for Western Blotting detection. The Sf9 cells in the culture plate were fixed with pre-cooled methanol for 10 minutes, washed once with PBS, 5 minutes each time; the membrane was permeabilized with 0.1% TritonX-10 for 5 minutes, washed twice with PBS, 5 minutes each time; blocked with PBS containing 5% BSA at room temperature for 2 hours, and washed three times with PBS; Anti-RBD polyclonal antibody (Sino Biological, 40592-T62; Anti-RBD polyclonal antibody: PBS containing 5% BSA = 1:1000, v / v) diluted in PBS containing 5% BSA was added, and incubated overnight at 4°C; 5% Goat anti-rabbit IgG-FITC (Biyuntian, A0562; goat anti-rabbit IgG-FITC: PBS containing 5% BSA = 1:5000, v / v) diluted in BSA PBS, incubated at 37℃ in the dark for 2h, washed 3 times with PBS; added 4',6-diamidino-2-phenylindole (DAPI) and incubated at room temperature for 10min, washed 3 times with PBS; added a little 20% glycerol to cover the slides, and observed under a fluorescent inverted microscope. The results showed that Sf9 cells infected with recombinant baculovirus P2-S showed obvious green fluorescence, while Sf9 cells not infected with baculovirus had no fluorescence ( Figure 4A); According to the same method as above, Anti-His monoclonal antibody (Biyuntian, AF5060; Anti-His monoclonal antibody: PBS containing 5% BSA = 1:1000, v / v) was used as primary antibody, and goat anti-mouse IgG-FITC (Biyuntian, A0568; goat anti-mouse IgG-FITC: PBS containing 5% BSA = 1:5000, v / v) was used as secondary antibody to identify the expression of M protein; Anti-Flag monoclonal antibody ( The expression of E protein was identified by using the primary antibody (Biyuntian, AF519; Anti-Flag monoclonal antibody: PBS containing 5% BSA = 1:1000, v / v) and the secondary antibody (Biyuntian, A0568; Goat anti-mouse IgG-FITC: PBS containing 5% BSA = 1:5000, v / v) to identify the expression of E protein. The results showed that Sf9 cells infected with the recombinant baculovirus P2-ME showed green fluorescence, while Sf9 cells not infected with the virus showed no fluorescence ( Figure 4 B,C).

[0078] (2) Western Blotting: The culture supernatant of Sf9 cells infected with P2-S virus or P2-ME virus was added with loading buffer at a ratio of 4:1 (P2-S virus or P2-ME virus infected Sf9 cell culture supernatant: loading buffer = 4:1, v / v), and incubated at 95°C for 10 min; 12% polyacrylamide separation gel and 5% stacking gel were prepared, and electrophoresis was performed at 22 mA constant current for 75 min; the protein was transferred to NC membrane, blocked at room temperature for 2 h (PBST containing 5% skim milk powder), and washed 3 times with PBST, 5 min / time; Anti-S monoclonal antibody (Sino Biological, 40592-MM117; 1:1000), incubated overnight on a shaker at 4°C, washed 5 times with PBST, 5 min / time; added goat anti-rabbit IgG-HRP (ABClone, AS003; 1:5000) diluted in PBST containing 5% BSA, incubated on a shaker at room temperature for 1 hour, washed 7 times with PBST, 5 min / time; used ECL substrate for color development, the results showed that the samples of the P2-S virus and P2-ME virus infection groups could react with specific antibodies, and the band size was consistent with expectations ( Figure 5 ).

[0079] Example 2 Preparation, purification and identification of SARS-CoV-2 virus-like particle VLP vaccine

[0080] 1. Co-infection of Sf9 cells with P2-S and P2-ME

[0081] One day before infection, prepare a 250 mL cell culture shake flask and culture 1×10 6Sf9 cells / mL were inoculated into the culture flask, and the total volume of the culture medium was 50 mL; the shake flask was placed in a shaker at 27°C, 120 r / min, dry, and CO2-free for 3-5 days to increase the cell density to 2×10 6 viable cells / mL, with a viability of ≥90%; P2-S and P2-ME viruses (MOI=5) were inoculated into a shake flask at a ratio of 1:1 and cultured at 27°C and 120 r / min for 96 h.

[0082] 2. Purification of SARS-CoV-2 VLPs using sucrose density gradient ultracentrifugation

[0083] After 96 hours of co-infection, the cells were counted and the viability was observed. When the viability was 60%-80%, the cells were transferred to a 50 mL centrifuge tube, centrifuged at 4°C, 3000 r / min for 15 min, and the cell pellet was resuspended with 5 mL PBS; the cells were lysed using an ultrasonic disruptor and centrifuged at 4°C, 12000 r / min for 10 min; the cell lysis supernatant sample was filtered using a 0.45 μm filter and placed on ice; pre-cooled 60%, 30%, and 20% sucrose were added to the ultracentrifuge tube in sequence, and then the cell lysis supernatant sample was slowly added to the ultracentrifuge tube, and ultracentrifuged at 4°C, 24100 r / min for 4.5 h; a milky white ring band appeared at the junction of 20%-30% and 30%-60% sucrose ( Figure 6 A), after being drawn out, resuspended with an appropriate amount of PBS, and ultracentrifuged at 4°C, 24100r / min for 1.5h to remove sucrose; discard the supernatant, add 1mL PBS to each ultracentrifuge tube to resuspend SARS-CoV-2 VLPs, and store at 4°C.

[0084] 3. SARS-CoV-2 VLPs Identification

[0085] (1) Western Blotting Identification: The purified SARS-CoV-2 VLPs sample was added to the loading buffer at a ratio of 4:1 (purified VLPs sample: loading buffer = 4:1, v / v), and incubated at 95°C for 10 min; 12% polyacrylamide separation gel and 5% concentrating gel were prepared, and electrophoresis was performed at 22 mA constant current for 75 min; the protein was transferred to the NC membrane, blocked at room temperature for 2 h (PBST containing 5% skim milk powder), and washed 3 times with PBST, 5 min / time; mouse anti-S monoclonal antibody (Sino Biological, 40592-MM117; 1:1000), incubated overnight at 4°C on a shaker, washed 5 times with PBST, 5 min / time; added goat anti-rabbit IgG-HRP (1:5000) diluted in PBST containing 5% BSA, incubated at room temperature on a shaker for 1 hour, washed 7 times with PBST, 5 min / time; used ECL substrate for color development, the results showed that the samples at 30%-60% of the cell lysis supernatant simultaneously showed S, M and E protein specific bands ( Figure 6 B).

[0086] (2) Transmission electron microscopy observation: 10 μL of purified VLPs sample was placed on a 200-mesh copper grid, adsorbed for 6 min at room temperature, and dried with filter paper. 2% phosphotungstic acid negative staining solution was added to the copper grid, negatively stained for 1 min, and the residual staining solution was removed with filter paper, and dried with a tungsten lamp. The morphology of VLPs was observed under a transmission electron microscope, and a capsule with a diameter of 50-100 nm was observed, with obvious crown-like structures on the surface. The morphological characteristics were similar to those of wild-type SARS-CoV-2 virus particles ( Figure 7 ).

[0087] (3) Immunoelectron microscopy observation: 10 μL of purified VLPs was added to a 200-mesh copper mesh and allowed to stand for 6 min. The sample was removed by absorbing the sample with the rough edge of filter paper. 10 μL of 1% BSA (prepared with high-pressure water filtered through a 0.22 μm filter) was added to the copper mesh and blocked for 50 s. The sample was quickly removed by absorbing the sample with the rough edge of filter paper. 10 μL of ultrapure water was added to wash away the blocking solution. The sample was allowed to stand for 30 s. The sample was removed by absorbing the sample with the rough edge of filter paper. The sample was repeated once. 10 μL of primary antibody, i.e., mouse anti-S monoclonal antibody (prepared with PBS filtered through a 0.22 μm filter, diluted 1:1000) was added. The sample was allowed to stand for 1 h at room temperature. The primary antibody was removed by absorbing the sample with the rough edge of filter paper. 10 μL of ultrapure water was added to allow the sample to stand for 30 s. s, remove with filter paper, repeat once; add 10 μL of secondary antibody, i.e., colloidal gold-labeled goat anti-mouse IgG (Solarbio, K1031G-Gold; prepared by filtering PBS with a 0.22 μm filter, diluted 1:20), incubate at room temperature for 1 hour, remove the secondary antibody with the rough edge of filter paper; add 10 μL of ultrapure water, let stand for 30 seconds, remove with filter paper, repeat once; add 10 μL of phosphotungstic acid negative staining solution, negative stain for 1 minute, remove the residual staining solution with the rough edge of filter paper, and dry with a tungsten lamp; observe VLPs under a transmission electron microscope, and the results show that VLPs labeled with specific antibody colloidal gold have a crown structure connected to the colloidal gold particles ( Figure 8 ).

[0088] (4) ACE2 binding activity: VLPs or OVA protein were diluted to 1 μg / mL with carbonate buffer (0.05 M, pH 9.6), 100 μL / well, and coated at 4°C overnight. The next day, the coating solution was discarded, the cells were washed three times with PBST, and patted dry. ELISA blocking solution (PBS containing 1% BSA) was added at 200 μL / well, blocked at 37°C for 2 h, the supernatant was discarded, the cells were washed three times with PBST, and patted dry. ACE2-Fc protein (Absin, abs04756; initial 100 μg / mL, 2-fold gradient method) diluted with blocking solution was added. dilution), 100 μL / well, incubate at 37°C for 2 h, discard the liquid, wash 5 times with PBST, and pat dry; add mouse anti-human IgG (Fc)-HRP enzyme-labeled antibody (GenScript, A01854; 1:5000 dilution), 100 μL per well, incubate at 37°C for 1 h; discard the enzyme-labeled antibody, wash 7 times with PBST, and pat dry; add 100 μL of single-component TMB colorimetric solution, incubate at 37°C in the dark for 10 min; add 2 mol / L H2SO4 stop solution, 50 μL / well, and read OD with a microplate reader 450 The results showed that compared with the OVA protein group and the PBS group, the binding activity of VLPs and ACE2 increased with the increase of ACE2 protein concentration and produced saturable binding, indicating that VLPs had a higher affinity with ACE2 ( Fig. 9 ).

[0089] Example 3 SARS-CoV-2 VLPs immunogenicity study

[0090] 1. Animal Immunization and Sample Collection

[0091] Twenty-four female BALB / c mice aged 6-8 weeks (purchased from Beijing Weitong Lihua Experimental Animal Co., Ltd.) were randomly divided into 4 groups, with 6 mice in each group, namely PBS group, 10μg VLPs immunization group, 10μg VLPs mixed with 20μg FliC adjuvant (VLPs+FliC) immunization group, and 10μg VLPs mixed with Alum adjuvant 1:1 (w / v) (VLPs+Alum) immunization group. The immunization method was intraperitoneal injection, and the immunization dose was 100μL / mouse. Mice were immunized on day 0, and booster immunization was performed on days 14 and 28, respectively. Two weeks after the third immunization, the mice were bled from the eye sockets to detect the levels of IgG, IgG subtypes and neutralizing antibodies in the mouse serum; in addition, the mouse spleen lymphocytes were collected to determine their proliferation capacity and the number of lymphocytes secreting IFN-γ and IL-4 cytokines, which were used to evaluate the level of humoral and cellular immune responses induced by VLPs.

[0092] 2. Detection of SARS-CoV-2 VLPs-specific IgG and its subtypes in serum

[0093] SARS-CoV-2 VLPs were diluted to 0.2 μg / mL with carbonate buffer, 100 μL per well, and coated overnight at 4°C; the coating solution was discarded, and the ELISA plate was washed 3 times with PBST containing 0.05% Tween-20, 5 min / time, and patted dry; PBS containing 1% BSA was added, 200 μL / well, and blocked at 37°C for 2 h; the liquid was shaken off, and the plate was washed 3 times with PBST, 5 min / time, and patted dry; the mouse serum of each group after the second and third immunizations diluted with blocking solution (initial ratio 1:100, 2-fold dilution gradient dilution) was added, 100 μL / well, and incubated at 37°C for 2 h; the ELISA plate was washed 5 times with PBST, 5 min / time, and patted dry; enzyme-labeled secondary antibodies (IgG-HRP (ABClone, AS003; 1:5000 dilution), IgG1-HRP (Southern Biotech, 1071-05; 1:3000 dilution), IgG2a-HRP (Southern Biotech, 1081-05; 1:3000 dilution), add 100 μL to each well, incubate at 37°C for 1 hour; wash the enzyme label 7 times with PBST, 5 min / time, and pat dry; add 100 μL TMB colorimetric solution to each well, incubate at 37°C in the dark for 10 min; add 2 mol / L H2SO4 stop solution, 50 μL / well, and read OD with a microplate reader 450 Value. (P(OD 450value)-N(negative control OD 450 value)) / (C(blank control OD 450 value)-N(negative control OD 450 The results showed that 12 days after the second and third immunizations, the antibody levels in the VLPs immunization group were significantly higher than those in the PBS control group; the antibody levels in the FliC group and the Alum adjuvant (ThermoFisher, 77161) group were significantly higher than those in the VLPs group ( Fig.10 ). 12 days after the three immunizations, the IgG1 and IgG2a antibody levels in the VLPs immunization group were significantly higher than those in the PBS group; the IgG1 and IgG2a antibody levels in the FliC adjuvant group were significantly higher than those in the VLPs immunization group; the IgG1 antibody level in the Alum adjuvant immunization group was significantly higher than that in the VLPs group ( Fig.11 ).

[0094] 3. Neutralizing antibody level detection

[0095] Two weeks after the three immunizations, the serum of each group of mice and the reagent were diluted according to the instructions of the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit (ELISA)-Multiplex VOC Kit (GenScript, L00871): the serum of each group of mice was diluted (sample dilution buffer: mouse serum = 9:1, v / v); the standard stock was diluted to 600U / mL with the sample diluent as a positive control, and the sample diluent was used as a negative control; the diluted serum, positive control or negative control were diluted with Probe RBD working solution (diluted serum, positive control or negative control: Probe RBD working solution = 2:1), added to a low-adsorption 96-well plate, shaken and mixed for 30s, and incubated at 37°C for 30min; 100μL of the mixed solution in the 96-well plate was transferred to the Capture Array The corresponding wells of the plate were covered with a cover film and incubated at 37°C for 15 min; the cover film was removed, the reaction solution was discarded, 260 μL of 1×Wash Solution was added to each well, and the washing solution was discarded after 30 s intervals, and the washing solution was repeated 4 times; 100 μL of enzyme-labeled antibody working solution was added to each well and incubated at 37°C for 15 min; the cover film was removed, the reaction solution was discarded, 260 μL of 1×Wash Solution was added to each well, and the washing solution was discarded after 30 s intervals, and the washing solution was repeated 4 times; 100 μL of TMB colorimetric agent was added to each well, and the reaction was incubated at 25°C in the dark for 15 min, and 50 μL of stop solution was added to each well to terminate the reaction; the OD was immediately read on an ELISA reader. 450The inhibition rate is used to determine the level of anti-SARS-CoV-2 neutralizing antibodies in the sample. The formula is as follows: Inhibition rate = (1-(sample OD 450 Value / negative control OD 450 The results showed that the VLPs, FliC and Alum adjuvant groups had higher inhibition rates, indicating that they can effectively induce the body to produce neutralizing antibodies ( Fig.12 ).

[0096] 4. Preparation of Splenic Lymphocyte Suspension

[0097] The mice in each group were euthanized 2 weeks after the three immunizations, and the spleens were removed under sterile conditions and placed in blood-free and antibiotic-free RPMI 1640 medium; the spleens were ground using the frosted surface of a glass slide and filtered into a centrifuge tube using a 70 μm cell mesh; RPMI 1640 medium was added, centrifuged at 1000 r / min for 5 min, and the supernatant was discarded; the cells were resuspended in 7 mL of complete RPMI 1640 medium (containing 1% penicillin-streptomycin solution and 10% FBS), and added to 7 mL of lymphocyte separation solution (Sigma, 10771); centrifuged at 1800 r / min for 20 min at room temperature, and the white cloudy cells in the middle, i.e., spleen lymphocytes, were collected; the spleen lymphocytes were washed using RPMI 1640 complete medium, and centrifuged at 1000 r / min for 5 min; the spleen lymphocytes were resuspended in 1.5 mL of RPMI 1640 complete medium and counted.

[0098] 5.Brdu-based cell proliferation assay

[0099] The Brdu-based Cell Proliferation ELISA kit (Roche, 11647229001) was used to detect the proliferation level of spleen lymphocytes. The specific steps were as follows: the spleen lymphocyte resuspension was added to a 96-well cell culture plate, and 2×10 5100 μL per well; add 10 μg / mL SARS-CoV-2 VLPs to stimulate cells, 100 μL / well, and set RPMI 1640 medium blank control group, each group has 2 replicates, 37 ℃, 5% CO2 incubator culture for 48h; add 20μL / well BrdU marker to make the final concentration of 10mM, 37 ℃, 5% CO2 continue to culture for 12h; 96-well cell culture plate is centrifuged at 1000r / min for 10min to make the cells adhere to the wall, the medium is discarded, and the cells are dried in a 60℃ constant temperature oven for 1h; FixDenat fixation solution is added, 200μL / well, and incubated for 30min to fix the BrdU-labeled DNA in the cells; the cells are washed twice with PBS, 100μL peroxidase-coupled anti-BrdU antibody is added, and incubated for 90min; the cells are washed 3 times with PBS, 100μL / well TMB colorimetric solution is added; 50μL H2SO4 is used to terminate the reaction, and the OD is read by a microplate reader 450 and OD 690 The stimulation index (SI) was calculated according to the following formula: SI = (OD 450 -OD 690 ) / (OD of untreated group 450 -OD 690 ). The results showed that the mouse lymphocyte stimulation index (SI) of the VLPs group was significantly higher than that of the PBS control group, indicating that VLPs can promote the proliferation and activation of splenic lymphocytes; compared with the VLPs immunization group, the splenic lymphocytes of the FliC adjuvant group (VLPs+FliC) had significantly increased cell proliferation levels under the stimulation of specific antigen VLPs ( Fig.13 ).

[0100] 6.ELISpot detection of secretion of IFN-γ and IL-4

[0101] Mouse IFN-γ ELISPOT Set (BD, 551083) and Mouse IL-4 ELISPOT Set (BD, 551017) were used to detect the number of spleen lymphocytes secreting IFN-γ and IL-4, respectively. The specific steps were as follows: the capture antibodies IFN-γ and IL-4 were diluted to 2 μg / mL with Dulbecco's phosphate buffered saline (DPBS), added to a 96-well ELISpot plate, 100 μL per well, and coated overnight at 4°C; the next day, after washing twice with RPMI 1640 medium, 100 μL RPMI 1640 medium was added to each well and blocked at room temperature for 2 h; 100 μL of the spleen lymphocyte suspension of each group of mice was added, a total of 2×10 5cells / well, stimulate cells with 5μg / mL SARS-CoV-2 VLPs, 100μL / well, incubate in a 37℃, 5% CO2 incubator for 24h; discard the cell suspension, wash twice with ddH2O, wash three times with PBST, 5min / time; add 100μL / well biotin-labeled detection antibodies (biotin-IFN-γ and biotin-IL-4) respectively, incubate at room temperature for 2h; wash the 96-well ELISpot plate with PBST for 5 times, 5min / time; add 100μL / well streptavidin-HRP (Abcam, ab7403; 1:1000 dilution), incubate at room temperature for 1h; wash the 96-well ELISpot plate with PBST for 5 times, 5min / time; add 100μL / well BCIP / NBT liquid substrate (Sigma, B1911) for reaction, terminate the reaction with ddH2O when blue appears, air-dry at room temperature until completely dry, and read through Bioreader The number of spots was analyzed by scanning the ELISpot readersystem in the 5000-Vβ instrument. The results showed that the number of spleen lymphocytes secreting IFN-γ and IL-4 in the VLPs group was significantly higher than that in the PBS group, indicating that VLPs can induce a mixed Th1 / Th2 immune response; the number of spleen lymphocytes secreting IFN-γ and IL-4 in the FliC adjuvant group was significantly higher than that in the VLP immunization group ( Fig.14 A), the number of spleen lymphocytes secreting IFN-γ in the Alum adjuvant group was not significantly different from that in the VLPs group, but the number of spleen lymphocytes secreting IL-4 was significantly higher than that in the VLPs immunization group ( Fig.14 B), indicating that FliC can enhance the ability of VLPs to induce Th1 / Th2 mixed immune response.

Claims

1. A gene encoding a structural protein of a novel coronavirus, characterized in that: The gene of the structural protein includes an S gene, an M gene or an E gene; the nucleotide sequence of the S gene is shown in SEQ ID NO.1; the nucleotide sequence of the M gene is shown in SEQ ID NO.2; and the nucleotide sequence of the E gene is shown in SEQ ID NO.

3.

2. A structural protein encoded by the gene according to claim 1.

3. An expression cassette, a recombinant vector, or a recombinant virus, characterized in that: A gene containing the structural protein according to claim 1.

4. A recombinant bacmid, characterized in that: It contains the recombinant vector according to claim 3.

5. A recombinant baculovirus, characterized in that It contains the recombinant bacmid according to claim 4.

6. A SARS-CoV-2 virus-like particle, characterized in that The recombinant baculovirus is purified by infecting Sf9 cells with the recombinant baculovirus described in claim 5.

7. A method for constructing the SARS-CoV-2 virus-like particle of claim 6, characterized in that: The following steps are involved: The recombinant vectors containing the S gene, M gene or E gene described in claim 1 are respectively transformed into competent cells, the recombinant bacmids are respectively transfected into Sf9 cells, and the recombinant baculoviruses co-infect the Sf9 cells to obtain the SARS-CoV-2 virus-like particles.

8. Use of the S gene, M gene or E gene according to claim 1, the structural protein according to claim 2, the expression cassette, the recombinant vector or the recombinant virus according to claim 3, the recombinant bacmid according to claim 4, the recombinant baculovirus according to claim 5, and the SARS-CoV-2 virus-like particle according to claim 6 in the preparation of a vaccine for preventing novel coronavirus infection.

9. Use of the S gene, M gene or E gene according to claim 1, the structural protein according to claim 2, the expression cassette, the recombinant vector or the recombinant virus according to claim 3, the recombinant bacmid according to claim 4, the recombinant baculovirus according to claim 5, and the SARS-CoV-2 virus-like particle according to claim 6 in the preparation of a drug for treating and / or preventing novel coronavirus infection.

Citation Information

Patent Citations

  • DNA molecule and recombinant virus, preparation method and application thereof

    CN106520789A

  • Detection kit for antigens of novel coronavirus (SARS-CoV-2)

    CN111303254A

  • Construction of chimeric SARS-CoV-2 VLP for expressing novel coronavirus S gene and flu M1 gene

    CN111676248A

  • Immunochromatographic test paper for detecting novel coronavirus

    CN111879933A

  • Detection of SARSr-CoV) antibodies

    CN111983226A

Cited By

  • Novel coronavirus trivalent DNA vaccine and preparation method thereof

    CN120099038A